Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 11/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.53 |
| ▸ | P4HTM | Q9NXG6 | 3/20 | 0.44 |
| ▸ | ALKBH2 | Q6NS38 | 3/20 | 0.44 |
| ▸ | FTO | Q9C0B1 | 3/20 | 0.44 |
| ▸ | ALKBH5 | Q6P6C2 | 2/20 | 0.44 |
| ▸ | ALKBH3 | Q96Q83 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15133393 | 0.85 | PTGS2 (0.57) | PTGS2PTGS1P4HTMALKBH2FTO | |
| SCHEMBL6403465 | 0.84 | PTGS2 (0.56) | PTGS2PTGS1P4HTMALKBH2FTO | |
| SCHEMBL10264908 | 0.83 | PTGS2 (0.51) | PTGS2PTGS1ALKBH2FTOALKBH5 | |
| SCHEMBL6403129 | 0.81 | PTGS2 (0.49) | PTGS2PTGS1P4HTMALKBH2FTO | |
| SCHEMBL6404681 | 0.80 | PTGS2 (0.50) | PTGS2PTGS1P4HTMALKBH2FTO | |
| SCHEMBL30845788 | 0.78 | GLS (0.37) | — | |
| SCHEMBL2731383 | 0.77 | PTGS1 (0.44) | PTGS2PTGS1 | |
| SCHEMBL10204165 | 0.77 | PTGS2 (0.56) | PTGS2PTGS1P4HTMALKBH2FTO | |
| SCHEMBL10204162 | 0.77 | NPC1 (0.63) | PTGS2PTGS1P4HTMALKBH2FTO | |
| SCHEMBL10204166 | 0.76 | PTGS2 (0.55) | PTGS2PTGS1ALKBH2FTOALKBH5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9023850-B2 | Nematocidal sulfonamides | E I DU PONT DE NEMOURS AND COMPANY (US) | 2015-05-05 | — | — | US | disclosed |
| US-20130190172-A1 | NEMATOCIDAL SULFONAMIDES | E I DU PONT DE NEMOURS AND COMPANY (US) | 2013-07-25 | — | — | US | disclosed |
| WO-2012054233-A1 | NEMATOCIDAL SULFONAMIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190172-A1 | NEMATOCIDAL SULFONAMIDES | QSOX1, ARSA, NOX1 | PTGS2 995/4885PTGS1 304/4885P4HTM 3231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.